Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Helga Gardarsdottir

Associate professor

Utrecht University

Netherlands

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Epidemiology

20%

Pharmacotherapy

100%

Drug Safety

60%

Evidence-based Medicine

40%

Pharmacoepidemiology

30%

Comparative Effectiveness Research

30%

European Union Regulation

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles14

Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018–2021: A Qualitative Analysis of Industry‐Sponsored Post‐Authorization Safety Studies

Article Link

Year:

2024

Real‐World Evidence to Inform Regulatory Decision Making: A Scoping Review

Article Link

Year:

2024

Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review

Article Link

Year:

2024

Which Benefits Can Justify Risks in Research?

Article Link

Year:

2024

Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021

Article Link

Year:

2023

Unintended impact of pharmacovigilance regulatory interventions: A systematic review

Article Link

Year:

2023

Review of studies evaluating effectiveness of risk minimisation measures assessed by the European Medicines Agency between 2016 and 2021

Article Link

Year:

2023

Impact of a Treatment Guide on Intravenous Fluids in Minimising the Risk of Hospital-Acquired Hyponatraemia in Denmark

Article Link

Year:

2023

Direct‐to‐participant investigational medicinal product supply in clinical trials in Europe: Exploring the experiences of sponsors, site staff and couriers

Article Link

Year:

2023

Prescribing of low‐dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands

Article Link

Year:

2023

The role of Real-World Data and evidence in oncology medicines approved in EU in 2018–2019

Article Link

Year:

2023

Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study

Article Link

Year:

2023

Which decentralised trial activities are reported in clinical trial protocols of drug trials initiated in 2019–2020? A cross-sectional study in ClinicalTrials.gov

Article Link

Year:

2022

Impact of regulatory interventions to restrict the combined use of renin–angiotensin system blockers: A Danish nationwide drug utilisation study

Article Link

Year:

2022

Collaborators11

Satu J Siiskonen

Utrecht University

NETHERLANDS

Sharon Essink

Utrecht University

NETHERLANDS

Helle Wallach-Kildemoes

Københavns Universitet

DENMARK

Patrick Souverein

Utrecht University

NETHERLANDS

Christine Hallgreen

Københavns Universitet

DENMARK

Saskia Le Cessie

Leiden University

NETHERLANDS

Tomas Lasys

Utrecht University

NETHERLANDS

Ghislaine van Thiel

Associate professor Medical Ethics

University Medical Center Groningen

NETHERLANDS

Rolf Groenwold

Professor of Clinical Epidemiology

Leiden University Medical Center

NETHERLANDS

Amos de Jong

Utrecht University

NETHERLANDS

Mira Zuidgeest

University Medical Center Utrecht, Utrecht University

NETHERLANDS

How do I reach out?

Meet Kite AI